Clinical Trial Update: 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 4-Hydroxytamoxifen or Tamoxifen Citrate for newly diagnosed Ductal carcinoma in situ (DCIS) in women, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• 4-hydroxytamoxifen (4-hydroxytamoxifen)
• Tamoxifen citrate (tamoxifen citrate)

Snippet

Sponsor: Northwestern University | Conditions: Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-07-21